Pharmacologic therapy for the treatment of asthma in children

L Waikart1, M S Blaiss

  • 1Department of Clinical Allergy and Immunology, University of Tennessee Health Science Center, Memphis, TN, USA.

Minerva Pediatrica
|October 2, 2004
PubMed

Insights

Pediatric asthma treatment requires comprehensive strategies, focusing on controller medications to manage inflammation. Current guidelines offer flexible, evidence-based options tailored to asthma severity classifications for effective management.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Childhood asthma presents a significant global health challenge with increasing prevalence.
  • Effective management necessitates aggressive and standardized treatment programs.
  • Advances in understanding asthma mechanisms drive improved pharmacologic therapies.

Purpose of the Study:

  • To review current pharmacologic treatments for pediatric asthma.
  • To discuss medication actions, side effects, efficacy, and indications.
  • To highlight the role of controller medications in managing underlying inflammation.

Main Methods:

  • Review of available medications for acute and chronic asthma symptoms.
  • Analysis based on established severity classifications: mild intermittent, mild persistent, moderate persistent, and severe persistent.
  • Examination of treatment guidelines incorporating evidence of effectiveness and safety.

Main Results:

  • A variety of medications are available for pediatric asthma.
  • Controller medications targeting inflammation are crucial for long-term management.
  • Treatment selection is guided by asthma severity and evidence-based guidelines.

Conclusions:

  • Current pediatric asthma treatment emphasizes controller medications for inflammation.
  • Evidence-based guidelines provide a flexible framework for selecting appropriate therapies.
  • Personalized treatment based on severity classification is key for effective pediatric asthma management.

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: